ERBB2 and breast carcinoma: Conventional assayssuch as immunohistochemistry (IHC) and in situ hybridization(ISH) used in clinical proceduresfor quantification of the human epidermal growth factor receptor-2(HER2) status in breast cancer have many limitations.